首页 | 本学科首页   官方微博 | 高级检索  
     

糖尿病前期和新诊断2型糖尿病患者血清血管内皮生长因子B水平与胰岛素抵抗的相关性
引用本文:童国玉,李翠柳,杨东辉,王维敏,沈山梅. 糖尿病前期和新诊断2型糖尿病患者血清血管内皮生长因子B水平与胰岛素抵抗的相关性[J]. 现代生物医学进展, 2019, 19(21): 4049-4054
作者姓名:童国玉  李翠柳  杨东辉  王维敏  沈山梅
作者单位:南京大学医学院附属鼓楼医院内分泌科 江苏 南京 210008
基金项目:南京市医药卫生科研重点项目(ZKX16036);中华医学会临床医学科研专项基金项目(13020210406)
摘    要:目的:探讨在糖尿病前期和新诊断2型糖尿病(T2DM)患者血清血管内皮生长因子B(VEGF-B)与胰岛素抵抗(IR)的关系。方法:选取2011年7月至2013年12月在我院内分泌科门诊就诊的患者419例,其中160例糖耐量正常(NGT)、142例糖尿病前期、117例新诊断T2DM患者,采用ELISA法测定血清VEGF-B水平,进一步分析血清VEGF-B水平与胰岛功能、胰岛素敏感性、肥胖及糖脂代谢相关代谢指标间的相关性。结果:血清VEGF-B水平在NGT (130.8 pg/mL [IQR 61.3-227.5])、糖尿病前期(146.7pg/mL [84.1-214.9])和T2DM(135.3 pg/mL [58.3-214.8])三组间无显著差异(P0.05)。相关分析显示血清VEGF-B水平与体重指数(BMI)、腰臀比(WHR)、血脂谱、胰岛功能及胰岛素敏感性均无相关性(P0.05)。结论:在糖尿病前期和新诊断T2DM患者,血清VEGF-B水平与肥胖、血脂谱、胰岛功能和胰岛素敏感性均无显著相关性,VEGF-B在人胰岛素抵抗及T2DM的发生中可能作用有限,仍需进一步研究明确其在代谢中的作用。

关 键 词:2型糖尿病;血管内皮生长因子B;胰岛素抵抗
收稿时间:2019-02-28
修稿时间:2019-03-23

Association between Serum Vascular Endothelial Growth Factor B and Insulin Resistance in Pre-diabetes and Newly Diagnosed Type 2 Diabetic Patients
TONG Guo-yu,LI Cui-liu,YANG Dong-hui,WANG Wei-min,SHEN Shan-mei. Association between Serum Vascular Endothelial Growth Factor B and Insulin Resistance in Pre-diabetes and Newly Diagnosed Type 2 Diabetic Patients[J]. Progress in Modern Biomedicine, 2019, 19(21): 4049-4054
Authors:TONG Guo-yu  LI Cui-liu  YANG Dong-hui  WANG Wei-min  SHEN Shan-mei
Affiliation:Department of Endocrinology, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu, 210008, China
Abstract:ABSTRACT Objective: To investigate the association between serum vascular endothelial growth factor (VEGF)-B and insulin resistance in pre-diabetes and newly diagnosed type 2 diabetes mellitus (T2DM) patients. Methods: Fasting serum VEGF-B levels were measured using ELISA in 160 normal glucose tolerance (NGT), 142 pre-diabetes, and 117 newly diagnosed T2DM subjects, and their association with insulin secretion, insulin sensitivity, parameters of adiposity, glucose and lipid metabolism was studied. Results: Fasting serum VEGF-B levels did not differ among NGT (130.8 pg/mL [IQR 61.3-227.5]), pre-diabetes (146.7 pg/mL [84.1-214.9]), and T2DM patients (135.3 pg/mL [58.3-214.8]) (all P>0.05). Correlated analysis showed that no significant association was found with body mass index (BMI), waist-to-hip ratio (WHR), lipid profiles, insulin secretion and sensitivity, as measured by a 75-g oral glucose tolerance test. Conclusion: Fasting serum VEGF-B levels are not related to adiposity, lipid profiles, insulin secretion and sensitivity in humans. These findings demonstrated that VEGF-B may be dispensable for insulin resistance and type 2 diabetes in humans.
Keywords:Type 2 diabetes   Vascular endothelial growth factor B   Insulin resistance
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号